[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Harbeck, N. and Gnant, M. (2017) Breast Cancer. The Lancet, 389, 1134-1150.
https://doi.org/10.1016/S0140-6736(16)31891-8
|
[3]
|
Van Asten, K., Neven, P., Lintermans, A., et al. (2014) Aromatase Inhibitors in the Breast Cancer Clinic: Focus on Exemestane. Endocrine-Related Cancer, 21, R31-R49. https://doi.org/10.1530/ERC-13-0269
|
[4]
|
Condorelli, R. and Vaz-Luis, I. (2018) Managing Side Effects in Adju-vant Endocrine Therapy for Breast Cancer. Expert Review of Anticancer Therapy, 18, 1101-1112. https://doi.org/10.1080/14737140.2018.1520096
|
[5]
|
Auton, A., Brooks, L.D., et al. (2015) A Global Reference for Human Genetic Variation. Nature, 526, 68-74.
https://doi.org/10.1038/nature15393
|
[6]
|
Blok, E.J., Derks, M.G., Van Der Hoeven, J.J., et al. (2015) Extended Adjuvant Endocrine Therapy in Hormone-Receptor Positive Early Breast Cancer: Current and Future Evidence. Cancer Treatment Reviews, 41, 271-276.
https://doi.org/10.1016/j.ctrv.2015.02.004
|
[7]
|
Oesterreich, S., Henry, N.L., Kidwell, K.M., et al. (2015) Associa-tions between Genetic Variants and the Effect of Letrozole and Exemestane on Bone Mass and Bone Turnover. Breast Cancer Research and Treatment, 154, 263-273.
https://doi.org/10.1007/s10549-015-3608-8
|
[8]
|
Ingle, J.N., Schaid, D.J., Goss, P.E., et al. (2010) Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase In-hibitors. Journal of Clinical Oncology, 28, 4674-4682.
https://doi.org/10.1200/JCO.2010.28.5064
|
[9]
|
Wang, J., Lu, K., Song, Y., et al. (2015) RANKL and OPG Poly-morphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients. PLoS ONE, 10, e0133964.
https://doi.org/10.1371/journal.pone.0133964
|
[10]
|
Coates, A.S., Keshaviah, A., Thurlimann, B., et al. (2007) Five Years of Letrozole Compared with Tamoxifen as Initial Adjuvant Therapy for Postmenopausal Women with Endo-crine-Responsive Early Breast Cancer: Update of Study BIG 1-98. Journal of Clinical Oncology, 25, 486-492. https://doi.org/10.1200/JCO.2006.08.8617
|
[11]
|
Arimidex, T., et al. (2008) Effect of Anastrozole and Tamoxifen as Adjuvant Treatment for Early-Stage Breast Cancer: 100-Month Analysis of the ATAC Trial. The Lancet Oncology, 9, 45-53.
https://doi.org/10.1016/S1470-2045(07)70385-6
|
[12]
|
Coombes, R.C., Kilburn, L.S., Snowdon, C.F., et al. (2007) Survival and Safety of Exemestane versus Tamoxifen after 2-3 Years’ Tamoxifen Treatment (Intergroup Exemestane Study): A Randomised Controlled Trial. The Lancet, 369, 559-570. https://doi.org/10.1016/S0140-6736(07)60200-1
|
[13]
|
Mao, J.J., Stricker, C., Bruner, D., et al. (2009) Patterns and Risk Factors Associated with Aromatase Inhibitor-Related Arthralgia among Breast Cancer Survivors. Cancer, 115, 3631-3639. https://doi.org/10.1002/cncr.24419
|
[14]
|
Crew, K.D., Greenlee, H., Capodice, J., et al. (2007) Preva-lence of Joint Symptoms in Postmenopausal Women Taking Aromatase Inhibitors for Early-Stage Breast Cancer. Journal of Clinical Oncology, 25, 3877-3883.
https://doi.org/10.1200/JCO.2007.10.7573
|
[15]
|
Mao, J.J., Su, H.I., Feng, R., et al. (2011) Association of Func-tional Polymorphisms in CYP19A1 with Aromatase Inhibitor Associated Arthralgia in Breast Cancer Survivors. Breast Cancer Research, 13, R8.
https://doi.org/10.1186/bcr2813
|
[16]
|
Niravath, P. (2013) Aromatase Inhibitor-Induced Arthralgia: A Review. An-nals of Oncology, 24, 1443-1449.
https://doi.org/10.1093/annonc/mdt037
|
[17]
|
Tenti, S., Correale, P., Cheleschi, S., et al. (2020) Aromatase Inhibi-tors-Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects. International Journal of Molecular Sciences, 21, 5625.
https://doi.org/10.3390/ijms21165625
|
[18]
|
Swenson, K.K., Nissen, M.J., Henly, S.J., et al. (2013) Identification of Tools to Measure Changes in Musculoskeletal Symptoms and Physical Functioning in Women with Breast Cancer Re-ceiving Aromatase Inhibitors. Oncology Nursing Forum, 40, 549-557. https://doi.org/10.1188/13.ONF.549-557
|
[19]
|
Roberts, K., Rickett, K., Greer, R., et al. (2017) Management of Aromatase Inhibitor Induced Musculoskeletal Symptoms in Postmenopausal Early Breast Cancer: A Systematic Review and Meta-Analysis. Critical Reviews in Oncology/Hematology, 111, 66-80. https://doi.org/10.1016/j.critrevonc.2017.01.010
|
[20]
|
Sestak, I., Cuzick, J., Sapunar, F., et al. (2008) Risk Factors for Joint Symptoms in Patients Enrolled in the ATAC Trial: A Retrospective, Exploratory Analysis. The Lancet Oncolo-gy, 9, 866-872.
https://doi.org/10.1016/S1470-2045(08)70182-7
|
[21]
|
Lombard, J.M., Zdenkowski, N., Wells, K., et al. (2016) Aromatase Inhibitor Induced Musculoskeletal Syndrome: A Significant Problem with Limited Treatment Options. Sup-portive Care in Cancer, 24, 2139-2146.
https://doi.org/10.1007/s00520-015-3001-5
|
[22]
|
Kanematsu, M., Morimoto, M., Honda, J., et al. (2011) The Time since Last Menstrual Period Is Important as a Clinical Predictor for Non-Steroidal Aromatase Inhibitor-Related Arthralgia. BMC Cancer, 11, Article No. 436.
https://doi.org/10.1186/1471-2407-11-436
|
[23]
|
于新颖, 文翠菊, 孙红娟, 等. 内分泌治疗绝经乳腺癌患者骨关节疼痛及其相关影响因素分析[J]. 中国实用医药, 2018, 13(32): 69-71.
|
[24]
|
Henry, N.L., Azzouz, F., Desta, Z., et al. (2012) Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Ear-ly-Stage Breast Cancer. Journal of Clinical Oncology, 30, 936-942.
https://doi.org/10.1200/JCO.2011.38.0261
|
[25]
|
Crew, K.D., Capodice, J.L., Greenlee, H., et al. (2010) Random-ized, Blinded, Sham-Controlled Trial of Acupuncture for the Management of Aromatase Inhibitor-Associated Joint Symptoms in Women with Early-Stage Breast Cancer. Journal of Clinical Oncology, 28, 1154-1160. https://doi.org/10.1200/JCO.2009.23.4708
|
[26]
|
Santa-Maria, C.A., Bardia, A., Blackford, A.L., et al. (2018) A Phase II Study Evaluating the Efficacy of Zoledronic Acid in Prevention of Aromatase Inhibitor-Associated Musculo-skeletal Symptoms: The ZAP Trial. Breast Cancer Research and Treatment, 171, 121-129. https://doi.org/10.1007/s10549-018-4811-1
|
[27]
|
Auton, A., Brooks, L.D., Durbin, R.M., et al. (2015) A Global Reference for Human Genetic Variation. Nature, 526, 68-74. https://doi.org/10.1038/nature15393
|
[28]
|
Michailidou, K., Beesley, J., Lindstrom, S., et al. (2015) Genome-Wide Association Analysis of More than 120,000 Individuals Iden-tifies 15 New Susceptibility Loci for Breast Cancer. Nature Genetics, 47, 373-380.
https://doi.org/10.1038/ng.3242
|
[29]
|
常培叶, 赵平. 单核苷酸多态性检测方法研究进展[J]. 中国老年学杂志, 2015, 35(16): 4720-4722.
|
[30]
|
杨春晓, 张玉, 师少军. SNP基因分型检测技术及应用进展[J]. 中国药师, 2013, 16(6): 811-816.
|
[31]
|
Gervasini, G., Jara, C., Olier, C., et al. (2017) Polymorphisms in ABCB1 and CYP19A1 Genes Affect Anastrozole Plasma Concentrations and Clinical Outcomes in Postmenopausal Breast Cancer Patients. British Journal of Clinical Pharmacology, 83, 562-571. https://doi.org/10.1111/bcp.13130
|
[32]
|
Park, I.H., Lee, Y.S., Lee, K.S., et al. (2011) Single Nucleotide Polymorphisms of CYP19A1 Predict Clinical Outcomes and Adverse Events Asso-ciated with Letrozole in Patients with Metastatic Breast Cancer. Cancer Chemotherapy and Pharmacology, 68, 1263-1271. https://doi.org/10.1007/s00280-011-1615-y
|
[33]
|
Fontein, D.B., Houtsma, D., Nortier, J.W., et al. (2014) Germline Variants in the CYP19A1 Gene Are Related to Specific Adverse Events in Aromatase Inhibitor Users: A Substudy of Dutch Patients in the TEAM Trial. Breast Cancer Research and Treatment, 144, 599-606. https://doi.org/10.1007/s10549-014-2873-2
|
[34]
|
Wang, J., Lu, K., Song, Y., et al. (2013) Indications of Clinical and Genetic Predictors for Aromatase Inhibitors Related Musculoskeletal Adverse Events in Chinese Han Women with Breast Cancer. PLoS ONE, 8, e68798.
https://doi.org/10.1371/journal.pone.0068798
|
[35]
|
Henry, N.L., Skaar, T.C., Dantzer, J., et al. (2013) Genetic As-sociations with Toxicity-Related Discontinuation of Aromatase Inhibitor Therapy for Breast Cancer. Breast Cancer Re-search and Treatment, 138, 807-816.
https://doi.org/10.1007/s10549-013-2504-3
|
[36]
|
Lintermans, A., Van Asten, K., Jongen, L., et al. (2016) Genetic Variant in the Osteoprotegerin Gene Is Associated with Aromatase Inhibitor-Related Musculoskeletal Toxicity in Breast Cancer Patients. European Journal of Cancer, 56, 31-36. https://doi.org/10.1016/j.ejca.2015.12.013
|
[37]
|
Garcia-Giralt, N., Rodriguez-Sanz, M., Prieto-Alhambra, D., et al. (2013) Genetic Determinants of Aromatase Inhibitor-Related Arthralgia: The B-ABLE Cohort Study. Breast Cancer Re-search and Treatment, 140, 385-395.
https://doi.org/10.1007/s10549-013-2638-3
|
[38]
|
Romero, S.A.D., Su, H.I., Satagopan, J., et al. (2020) Clinical and Genetic Risk Factors for Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors. Breast, 49, 48-54. https://doi.org/10.1016/j.breast.2019.10.008
|
[39]
|
Simonsson, M., Veerla, S., Markkula, A., et al. (2016) CYP1A2—A Novel Genetic Marker for Early Aromatase Inhibitor Response in the Treatment of Breast Cancer Patients. BMC Cancer, 16, Article No. 256.
https://doi.org/10.1186/s12885-016-2284-3
|